IBOV 183,827.59 ▲ 0.46% IPSA 11,055.91 ▼ 0.73% IPC MEX 65,071.30 ▲ 0.20% MERVAL 2,782,561 ▼ 0.59% COLCAP 2,558.92 ▼ 0.79% BVL PERÚ 60,220.45 ▲ 0.32% USD/BRL5.20▼ 0.43% USD/MXN18.08▲ 0.21% USD/CLP972.08▲ 0.38% USD/COP3,323▲ 0.62% USD/PEN3.44— 0.00% USD/ARS1,524▼ 0.05% USD/UYU40.27▲ 3.67% USD/PYG5,843▲ 2.30% USD/BOB11.96▲ 0.45% USD/DOP59.27▲ 0.12% USD/CRC452.68▲ 2.68% USD/GTQ7.64▲ 3.13% USD/HNL26.87▲ 3.23% USD/NIO36.62▲ 0.34% USD/VES856.92▲ 0.01% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD 157.28 — 0.00% USD/TTD6.70▲ 1.64% EUR/BRL5.90▲ 0.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73% IBOV 183,827.59 ▲ 0.46% IPSA 11,055.91 ▼ 0.73% IPC MEX 65,071.30 ▲ 0.20% MERVAL 2,782,561 ▼ 0.59% COLCAP 2,558.92 ▼ 0.79% BVL PERÚ 60,220.45 ▲ 0.32% USD/BRL 5.16 ▲ 0.01% USD/MXN 17.06 ▼ 0.24% USD/CLP 913.98 ▲ 0.04% USD/COP 3,140 ▲ 0.03% USD/PEN 3.36 ▼ 0.66% USD/ARS 1,493 ▲ 0.10% USD/UYU 40.27 ▲ 1.24% USD/PYG 5,939 ▲ 1.68% USD/BOB 11.64 ▼ 0.76% USD/DOP 58.34 ▲ 1.25% USD/CRC 445.92 ▲ 0.89% USD/GTQ 7.62 ▲ 2.21% USD/HNL 26.79 ▲ 1.57% USD/NIO 36.62 ▲ 0.69% USD/VES 762.44 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.28 — 0.00% USD/TTD 6.70 ▲ 0.61% EUR/BRL 5.95 ▲ 1.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73%
since 2009
Wednesday, September 30, 2026

Mixed Outcomes in European Markets; U.S. Approval Elevates AstraZeneca

By · February 19, 2024 · 2 min read

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “Argentina gives Britain two weeks over Falklands oil”

Free. We send a confirmation link first — nothing arrives until you click it. Unsubscribe with one click in any edition. If you stop opening us for 30 days we stop sending by ourselves, as we assume the interest is no longer there. See our privacy policy. We never share your email.

On February 19, European stock markets displayed mixed outcomes, halting a three-day gain streak.

The day’s trading was notably quiet, affected by a U.S. holiday and a lack of impactful news.

The spotlight was on London’s FTSE 100, which edged up by 0.22% to 7,728.50 points, thanks significantly to AstraZeneca’s shares, which soared by 3.21%.

Free daily brief — no card needed
Get every Market Reports story in one morning email
We build you a personalized brief around the topics you follow — free for 7 days. Love it? Your first month after that is US$1.

This surge came after the U.S. FDA approved AstraZeneca’s lung cancer drug, Tagrisso, for use in the United States, combined with chemotherapy.

This FDA approval marks Tagrisso as a key advancement in lung cancer treatment.

Mixed Outcomes in European Markets; U.S. Approval Elevates AstraZeneca
Mixed Outcomes in European Markets; U.S. Approval Elevates AstraZeneca.
One-stop reference
Company Intelligence
Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.
Browse the directory →
RT
Ask Rio Times
Latin American markets, currencies and companies.
Open the full Ask Rio Times →

Trials have shown that Tagrisso, with chemotherapy, lowers the risk of disease worsening or death by 38% compared to standard care.

Dave Fredrickson, AstraZeneca’s EVP of Oncology, highlights the treatment’s potential, delaying disease progression by nearly nine months.

AstraZeneca stands out within the “Granolas,” a category coined by Goldman Sachs to describe high-market-cap companies showing exceptional performance and surpassing broader market indices.

This group includes renowned firms like GSK, Roche, and Nestlé, highlighting AstraZeneca’s significant market impact.

Elsewhere, Frankfurt’s DAX dipped slightly by 0.15%, while Paris’s CAC 40 remained steady.

France revises economic growth forecast to 1% from 1.4%, citing global conflicts, China’s slowdown, and Germany’s recessionary pressures

In Madrid, the Ibex 35 climbed by 0.59%, with notable gains from Grifols, Telefonica, and CaixaBank.

Lisbon’s PSI 20 also saw an uptick, whereas Italy’s FTSE MIB experienced a minor decline.

Temenos shares in Switzerland surged over 8% in a significant recovery, following disputed allegations from Hindenburg Research.

Market movements underscore the complex dynamics of international finance, where corporate news like AstraZeneca’s drug approval impacts global trends.

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error

LatAm Markets: Live Signals → — real-time movers, turnover leaders and FX across Latin America.

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.